Materials and methods for inhibiting a viral infection, including a coronavirus infection
Inventors
Monsul, Nicholas T. • Berkes, Eva A. • BOEHM, Frederick T. • LIAO, Yu-Hsien
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11826390-B2
Publication Date
2023-11-28
Expiration Date
Abstract
The subject invention provides compositions and methods for inhibiting viral infections. Preferred embodiments of the invention provide pharmaceutical compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof.
Core Innovation
The invention relates to inhibiting a viral infection in a subject by administering a virally inhibiting effective amount of a composition. The composition comprises an isolated bioactive Lactobacillus fermentum bacterial strain grown as biofilm, and/or a virus-inhibiting extract of the biofilm, including coronavirus infections.
The Lactobacillus fermentum is identified as Lactobacillus fermentum Qi6 having Accession No. PTA-122195, and the biofilm phenotype is used to derive bioactive extracts. The described compositions include protein characterization of Qi611S (SEQ ID NO: 1) and its gene Qi611S (SEQ ID NO: 2), and the document also discusses recombinant expression of Qi611S.
The patent explains proposed mechanisms for viral infection inhibition through innate immune immunomodulation, including PPAR agonism, and possible ACE2-binding to block viral entry and/or spread. The scope includes use in acute/chronic treatment and prophylaxis, and it also describes formulation forms such as lyophilized/freeze-dried/lysate forms.
Claims Coverage
The independent claims cover administering a virally inhibiting effective amount of a biofilm-derived Lactobacillus fermentum composition, including an isolated bioactive strain grown as biofilm and/or a virus-inhibiting extract, specifically using Lactobacillus fermentum Qi6 having Accession No. PTA-122195, to inhibit viral infection in a subject. Six inventive features are identified, with refinements on virus identity, administration route, and combination context.
Biofilm-grown Lactobacillus fermentum Qi6 for viral infection inhibition
Administering to a subject in need thereof a virally inhibiting effective amount of a composition comprising an isolated bioactive Lactobacillus fermentum bacterial strain grown as biofilm and/or comprising a virus-inhibiting extract of said biofilm, wherein the Lactobacillus fermentum strain is Lactobacillus fermentum Qi6 having Accession No. PTA-122195.
RNA virus inhibition using the biofilm-derived Qi6 composition
The method further includes that the virus is an RNA virus.
SARS-CoV-2 inhibition using the biofilm-derived Qi6 composition
The method further includes that the virus is SARS-CoV-2 coronavirus.
Administration route set for delivery of the Qi6 biofilm composition
The method further includes administering the composition by a parenteral, oral, sublingual, nasal, or pulmonary route.
Parenteral route selection within injection subtypes
The method further includes that the parenteral route is selected from subcutaneous, intradermal, subdermal, intraperitoneal and intravenous injection.
Combination with one or more other antiviral therapies
The method further includes administering the specified composition together with one or more other antiviral therapies.
Overall, the claim coverage is anchored on inhibiting viral infection in a subject through administration of a biofilm-grown, isolated Lactobacillus fermentum Qi6 (PTA-122195) composition and/or a virus-inhibiting extract derived from that biofilm, with additional limitations specifying the targeted virus class and particular coronaviruses, as well as permissible delivery routes and combination therapy context.
Stated Advantages
High protection against porcine respiratory coronavirus (PRCV) is described for a biofilm extract (Qi601S) under the described conditions.
No cytotoxicity is described under the described conditions.
Documented Applications
Inhibiting viral infection in a subject, including coronavirus infections such as SARS, MERS, and SARS-CoV-2.
Prophylaxis and acute/chronic treatment are described for the compositions and methods.
Protection of cells against porcine respiratory coronavirus (PRCV) is described in example results.
Interested in licensing this patent?